Leptin and insulin share some hypothalamic signaling molecules but their central administration induces different effects on hepatic glucose fluxes. Acute insulin infusion in the third cerebral ventricle (ICV) inhibits endogenous glucose production (GP) while acute leptin infusion stimulates gluconeogenesis but does not alter GP due to a compensatory decrease in glycogenolysis. Since melanocortin agonists also stimulate hepatic gluconeogenesis, here we examined whether central melanocortin blockade modifies the acute effects of leptin on GP, on gluconeogenesis, on glycogenolysis, and/or on the hepatic expression of the gluconeogenic enzymes glucose 6-phosphatase (Glc-6-Pase) and phosphoenolpyruvate carboxykinase (PEPCK).
Introduction
Leptin, the 167 amino acid polypeptide product of the ob gene, is secreted by the adipose tissue and acts mainly on the central nervous system to regulate energy balance (1) .
Leptin regulates food intake and body adiposity partly via activation of melanocortin receptors in the hypothalamus and in other areas within the central nervous system (2;3).
It is now well recognized that leptin also plays an important role in the regulation of insulin action and intermediate metabolism (4) (5) (6) (7) (8) (9) . Indeed, prolonged administration of recombinant leptin to non-diabetic and diabetic rats (10) (11) (12) (13) as well as to lipodystrophic humans and mice (4;14) markedly improves in vivo insulin action. Similarly, bidirectional modulation of the activity of the central melanocortin pathway leads to significant changes in hepatic and peripheral insulin action (15) . On the other hand, the prolonged administration of either leptin or melanocortin agonists or antagonists also impacts on the distribution of body adiposity and on lipid homeostasis (10;15-18) . These effects are in turn likely to secondarily influence the in vivo action of insulin on metabolic parameters (15) . Thus, it is important to delineate the acute effects of leptin and melanocortins on metabolic fluxes prior to the onset of changes in energy balance, body composition, and lipid storage.
In this regard, acute administration of leptin to postabsorptive rats causes a marked re-distribution of intra-hepatic glucose fluxes, with a marked increase in the relative contribution of gluconeogenesis and a parallel decrease in the contribution of glycogenolysis to hepatic glucose output (5;6) . This effect is seen following either systemic or central administration of the hormone (5;6). Which are the mechanism(s) by which leptin stimulates gluconeogenesis and inhibits glycogenolysis? Leptin appears to exert its pleiotropic behavioral, metabolic, and neuro-endocrine actions via multiple and partly divergent central pathways (19;20) . For example, it has been suggested that leptin controls the hypothalamic melanocortin pathway and energy balance via STAT3-dependent signaling and the NPY pathway, reproductive function, and glucose homeostasis via STAT3-independent signaling (20;21) . Furthermore, leptin and insulin receptors appear to share mechanisms of signal transduction such as the activation of phosphatidylinositol-3-kinase (PI3K) (22;23) . These observations are intriguing since these two hormones have partly overlapping and partly divergent physiological actions (24) (25) (26) . Of particular interest, the acute ICV administration of insulin markedly inhibits endogenous glucose production (GP) via a PI3K-dependent mechanism (27) , while the acute administration of leptin stimulates gluconeogenesis and liver PEPCK expression (5;6).
To delineate the contribution of the central melanocortin pathway to the acute effects of leptin on glucose homeostasis we first examined whether and how the central activation of the melanocortin pathway modulates glucose fluxes and then we examined the contribution of the central melanocortin pathway to the acute effects of systemic and ICV leptin on glucose kinetics. Our results reveal specific and potent melanocortindependent and melanocortin-independent effects of leptin on hepatic glucose fluxes.
Methods
Animals and Experimental Design. Ten week-old male Sprague-Dawley (S-D) rats (Charles River Breeding Laboratories, Inc., Wilmington, MA) were housed in individual cages and subjected to a standard light dark cycle (0600-1800/1800-0600). Three weeks prior to the in vivo studies ( see figure 1B) , all rats received implantations of ICV catheters by stereotaxic surgery as previously described (6) . One week before the pancreatic-insulin clamp protocols, rats received additional catheters in the right internal jugular and left carotid artery as previously described (5;6). Rats were fed a standard chow (SC, cat. no. 5001, Purina Mills Ltd) and were allowed to recover completely before initiation of all in vivo studies.
Insulin action studies. Rats (n = 79) were implanted with chronic catheters as previously described (6) . After full recovery from the catheterization, animals were randomized into 8 groups receiving the following infusions for the duration of the in vivo study (6H, see figure 1C ): 1) ICV Vehicle, 2) ICV α-MSH (3 µg/6 h), 3) ICV Leptin (1.5 µg/6 h),4) IV Leptin (3 µg/kg·min); each of the above infusions were performed in the absence or presence of ICV SHU9119 (1 µg/6 h). At t = -2hr (Figure 1c) , a primedcontinuous infusion of ICV solutions was initiated and maintained throughout the duration of the study. Plasma glucose was measured periodically initiating at the onset (t = 2hr) of the ICV infusion and lasting throughout the duration of the study. Plasma samples for determination of insulin, leptin, and non-esterified fatty acid concentration were obtained at the onset (t = -2hr) and at 30 min intervals during the study. At t = 0, and a primed-continuous infusion of HPLC-purified H]-glucose (New England Nuclear, Boston, MA; 40 µCi bolus, 0.4 µCi/min for duration of the study) was initiated and maintained for the last four hours of the study. Samples for determination of 3 Hglucose specific activity were obtained at 10-minute intervals throughout infusions.
Finally, at t = 2hr, a pancreatic-insulin clamp study was initiated and maintained for two hours. During this procedure, a primed-continuous infusion of regular insulin (3 mU/kg.min) was administered, and a variable infusion of 25% glucose solution was started at t = 2 and periodically adjusted to clamp the plasma glucose concentration at ~ 7mM. The rate of insulin infusion was designed to obtain physiological hyperinsulinemia (see table 1 ). In order to control for possible effects of the ICV injections on endocrine pancreas, somatostatin (3µg/kg/min) was co-infused with insulin to inhibit endogenous islets secretion. At the end of the in vivo studies, rats were anesthetized (pentobarbital 55 mg/kg body weight, intravenously) and tissue samples were freeze-clamped in situ with aluminum tongs pre-cooled in liquid nitrogen. All tissue samples were stored at -80˚C for subsequent analysis.
The ICV vehicle was artificial cerebrospinal fluid (aCSF) while the IV vehicle was isotonic saline. Leptin used in these studies was recombinant mouse leptin (gift of Dr. M.
McCaleb, Amgen, Inc., Thousand Oaks, CA; >95% pure by SDS-PAGE).
Analytical procedures and Calculations. Plasma glucose was measured by the glucose oxidase method (Glucose Analyzer II, Beckman Instruments, Inc. Fullerton, California, USA). Plasma insulin and leptin levels were determined by RIA (rat Leptin RIA kit, Linco Research Inc., St. Charles, MO). Serum adiponectin was measured by RIA (Linco Research, Inc., St. Charles, MO). Plasma non-esterified fatty acid concentrations were determined an enzymatic method by an automated kit according to the manufacturer's specifications (Waco Pure Chemical Industries. Osaka, Japan). The radioactivity of [3- 3 H]glucose in plasma was measured from supernatants of Ba (OH) 2 and from ZnSO 4 precipitates (Somogyi procedure), after each was evaporated to dryness for the removal of tritiated water. The hepatic 14 C-phosphoenolpyruvate (PEP) and 3 H/ 14 C-UDP glucose specific activities (SA) were obtained by two sequential chromatographic separations, as previously described (28) (29) (30) (31) . Calculations were performed as described (32) . Briefly, the rates of PEP-gluconeogenesis (GNG), the flux through glucose-6-phosphatase (Glc-6-Pase flux) and glucose cycling (GC= Glc-6-Pase flux -GP) were calculated as previously described (33) . Gluconeogenesis was estimated from the specific activities of 14 C-labeled hepatic UDPglucose (assumed to reflect the specific activity of hepatic glucose-6- GAPDH. The copy mRNA number was calculated from standard curves obtained using plasmid DNA standards of known copy number for the each gene of interest.
Statistical analysis was done using unpaired Student's t test or analysis of variance.
The study protocol was reviewed and approved by the Institutional Animal Care and Use
Committee of the Albert Einstein College of Medicine.
Results
To investigate the mechanism by which leptin regulates glucose kinetics independently of its pleiotropic actions on energy balance and body composition, we examined whether and how acute modulation of the activity of central melanocortin receptors affect the action of leptin on hepatic and peripheral glucose fluxes. ICV catheters were implanted in male Sprague-Dawley rats by stereotaxic surgery (6) . All the infusion studies were performed ~3 weeks later following complete recovery from the operation ( Figure 1A ).
Activation of central melanocortin receptors leads to a marked increase in liver
gluconeogenesis. We first examined whether stimulation of central melanocortin Figure 1D ). Importantly, SHU9119 per se did not modify insulin's effect on GP, but it blocked the effect of ICV α-MSH. In Figure 1D , the effect of insulin on GP is expressed as per cent inhibition from basal levels. Insulin inhibited GP by 58±4% in the presence of ICV vehicle but by only 20±10% when ICV α-MSH was infused (p<0.01
vs. vehicle). When SHU9119 was co-infused ICV, α-MSH failed to alter the inhibitory action of insulin on GP (64±11%), while SHU9119 alone did not alter hepatic insulin action (60±11%). Thus, the stimulatory effect of the central administration of α-MSH on GP is specific since the selective inhibition of central melanocortin receptors is sufficient to negate the effects of ICV α-MSH on hepatic insulin action.
In the presence of physiological hyperinsulinemia, ICV α-MSH caused a 2-fold increase in the rate of GP ( Figure 2A ) as compared with the ICV vehicle-infused group.
This effect was abolished by the concomitant administration of SHU9119, while the ICV administration of an equal dose of the melanocortin antagonist per se did not modify GP.
To further delineate the mechanisms responsible for the effects of α-MSH on GP, we estimated the in vivo flux through glucose-6-phosphatase (Glucose-6-phosphatase flux in Table 1 ). The plasma glucose, insulin, leptin, and FFA concentrations were similar in the three groups prior and during the clamp procedure (Table 1) . During physiologic hyperinsulinemia (plasma insulin ~400 pM), the rate of glucose infusion required to maintain the plasma glucose concentration at basal levels was not affected by leptin alone, but it was significantly increased (by 75%) by the concomitant ICV infusion of SHU9119. The rates of glucose uptake (Rd) were similar in rats receiving systemic vehicle or leptin with or without ICV SHU9119 (p=NS) ( Figure 3B ). Conversely, the coinfusion of systemic leptin and ICV SHU9119 significantly enhanced the action of insulin in inhibiting GP ( Figure 3B ). In Figure 3B , the effect of insulin on GP is expressed as per cent inhibition from basal levels. Insulin inhibited GP by 55±5% in the presence of vehicle. Although leptin alone did not alter hepatic insulin action (47±4%), when ICV SHU9119 was co-infused systemic leptin resulted in enhanced suppression of GP (by 79±6%; p<0.01 vs. vehicle). Thus, the central administration of an antagonist of the melanocortin receptors unveils a potent melanocortin-independent effect of systemic leptin on hepatic insulin action.
To further delineate the mechanisms responsible for the effects of systemic leptin on GP, we estimated the in vivo flux through glucose-6-phosphatase (Glucose-6-phosphatase flux in Fig. 4B ) and the relative contributions of glycogenolysis (Fig. 4C) and gluconeogenesis (Fig. 4D) Figure   5A and Table I ). The plasma glucose, insulin, leptin, and FFA concentrations were similar in the three groups prior and during the clamp procedure (Table I) . During physiologic hyperinsulinemia (plasma insulin ~450 pM), the rate of glucose infusion required to maintain the plasma glucose concentration at basal levels was not affected by ICV leptin alone, but it was significantly increased (by ~20%) by the concomitant ICV infusion of SHU9119. The rates of glucose uptake (Rd) were similar in rats receiving ICV vehicle or leptin with or without ICV SHU9119 (p=NS) ( Figure 5B ). Conversely, the ICV co-infusion of leptin and SHU9119 significantly enhanced the action of insulin in inhibiting GP ( Figure 5B ). In Figure 5B , the effect of insulin on GP is expressed as per cent inhibition from basal levels. Insulin inhibited GP by 58±4% in the presence of ICV vehicle. Although ICV leptin alone did not alter hepatic insulin action (58±3%), when SHU9119 was co-infused ICV leptin resulted in enhanced suppression of GP (by 82±6%; p<0.01 vs. vehicle). Thus, the central administration of an antagonist of the melanocortin receptors unveils a potent melanocortin-independent effect of central leptin on hepatic insulin action.
To further delineate the mechanisms responsible for the effects of ICV leptin on GP, we estimated the in vivo flux through glucose-6-phosphatase (Glucose-6-phosphatase flux in Fig. 6B ) and the relative contributions of glycogenolysis (Fig. 6C) and gluconeogenesis ( The effects of leptin on hepatic glucose fluxes appear to be more complex than those of α-MSH. The systemic infusion of leptin during insulin clamp studies similarly increased the hepatic expression of PEPCK and Glc-6-Pase and the rate of gluconeogenesis, but it also markedly suppressed the rate of glycogenolysis so that GP was not increased. These changes induced by a physiological elevation in circulating leptin levels, recapitulates our previous findings in the presence of supra-physiological plasma levels of the hormone (5). When the stimulatory effect of systemic leptin on central melanocortin receptors was prevented, equal increases in circulating leptin concentrations failed to alter gluconeogenesis and liver PEPCK/Glc-6-Pase mRNA levels. However, under these experimental conditions increasing the plasma leptin concentration markedly inhibited the rate of glycogenolysis and therefore enhanced insulin's inhibition of GP. It should be pointed out that these insulin-like effects of systemic leptin on hepatic glucose fluxes could be mediated via direct effects on the liver as well as via extra-hepatic (presumably hypothalamic) actions of leptin. In this regard, leptin has also been shown to directly modulate insulin signaling, lipid metabolism, and glycogenolysis in some studies conducted in isolated liver cells (35;36) or perfused liver (37) . Conversely, the effects of a physiological increase in systemic leptin on the hepatic expression of gluconeogenic enzymes as well as on gluconeogenesis are centrally mediated since they were abolished by the central antagonism of melanocortin receptors.
In order to discern whether the melanocortin-independent effects of leptin on glycogenolysis and GP require increased liver exposure to leptin or they are also centrally mediated, we next examined the effects of central leptin administration with or without activation of central melanocortin receptors. Once again leptin markedly suppressed GP via decreased glycogenolysis, when the activation of central melanocortin receptors was prevented. Thus, leptin can inhibit hepatic glycogenolysis and GP via a central pathway.
This is consistent with the observation that neuron-specific deletion of leptin receptor expression largely recapitulates the behavioral and metabolic defects induced by the whole body loss-of-function in this receptor (50) .
While the CNS pathways and efferent signals mediating the melanocortinindependent effects of leptin on liver glycogenolysis are unknown, it is tempting to speculate that the activation of an 'insulin-like' signaling pathway within the hypothalamus plays a key role. Leptin and insulin can both increase the activity of PI3K
in the hypothalamus and this signaling pathway is involved in their anorectic effects (22;23) . Importantly, central activation of insulin signaling markedly suppresses GP and the effect of a physiological increase in circulating insulin on GP requires the central activation of PI3K (27) . Here we report metabolic effects of leptin via a melanocortinindependent signaling pathway that closely resemble the potent inhibitory effect of the central administration of insulin on GP. Taken together these findings support the notion that leptin's activation of PI3K in the hypothalamus may mediate its 'insulin-like' effect on GP and glycogenolysis.
It has long been recognized that the diminished ability of insulin to suppress glucose production by the liver (hepatic insulin resistance) is a main cause of hyperglycemia in type 2 diabetes mellitus. Our results indicate that leptin can modulate hepatic insulin action via melanocortin-dependent as well as via melanocortin-independent effects. In fact, leptin stimulates hepatic gluconeogenesis and PEPCK/Glc-6-Pase expression via central activation of melanocortin receptors, but it also markedly suppresses hepatic glycogenolysis via a central melanocortinindependent mechanism. Thus selective signaling (or selective resistance) via either of these two central circuits mediating the rapid actions of leptin on the liver can lead to dramatic changes in hepatic insulin action and glucose metabolism. In this regard, it will be important to discern whether common forms of leptin resistance symmetrically impact on the melanocortin-dependent and melanocortin-independent effects of leptin on liver glucose metabolism. 
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